Status:
RECRUITING
Inhaled and Intravenous Milrinone in Patients With Severe Pulmonary Hypertension
Lead Sponsor:
Zagazig University
Conditions:
Pulmonary Hypertension Due to Left Heart Disease
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The investigator compared difference between inhaled and intravenous milirinone in patiens with severe pulmonary hypertension undergoing cardiac surgery
Detailed Description
Milrinone is widely used in cardiac surgery as an inotrope and pulmonary vasodilator agent But , intravenous milrinone has been associated with systemic hypotension and increased requirement for vasoa...
Eligibility Criteria
Inclusion
- Patients scheduled to undergo mitral valve surgery by cardiopulmonary bypass with estimated mean pulmonary artery pressure =\>55 estimated by using preoperative Doppler echocardiography
Exclusion
- Patients were excluded if they had surgery without CPB, preoperative hemodynamic instability (defined as acute requirement for vasoactive support or mechanical device),Patients with severe LV dysfunction (LV ejection fraction of less than 30% congenital heart disease, a contraindication to transesophageal echocardiography (TEE), emergency surgery or re-do surgeries severe renal or hepatic disease
- , coagulopathy, and thromboembolic disease treated with anticoagulants
Key Trial Info
Start Date :
May 20 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 10 2025
Estimated Enrollment :
38 Patients enrolled
Trial Details
Trial ID
NCT04484675
Start Date
May 20 2023
End Date
May 10 2025
Last Update
April 30 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zagazig University
Zagazig, Sharqia Province, Egypt, 44519